Halozyme Therapeutics, Inc. (NASDAQ:HALO) major shareholder Randal J. Kirk sold 303,168 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $17.36, for a total transaction of $5,262,996.48. Following the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at $61,843,055.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

HALO opened at $17.17 on Friday. The firm has a market cap of $2.45 billion, a PE ratio of 38.16 and a beta of 1.93. The company has a quick ratio of 3.43, a current ratio of 3.49 and a debt-to-equity ratio of 0.31. Halozyme Therapeutics, Inc. has a one year low of $11.41 and a one year high of $21.48.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $35.20 million during the quarter, compared to analyst estimates of $31.49 million. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. sell-side analysts forecast that Halozyme Therapeutics, Inc. will post -0.82 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. SG Americas Securities LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $158,000. Element Capital Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $198,000. Piermont Capital Management Inc. bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $206,000. Raymond James & Associates bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $216,000. Finally, Eaton Vance Management bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $235,000. 84.70% of the stock is owned by institutional investors.

A number of research analysts have recently commented on the stock. BMO Capital Markets boosted their price target on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “market perform” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Wednesday, July 11th. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 22nd. Finally, TheStreet lowered shares of Halozyme Therapeutics from a “b-” rating to a “c” rating in a research report on Tuesday, May 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Hold” and an average price target of $21.50.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Further Reading: Technical Analysis

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.